Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia

Introduction. mBRAF mCRC has the aggressive phenotype. The incidence of such mutation in Europe and the USA is around 8–14%, in Asian countries – 4–8%. The purpose of this population-based study was to determine the incidence and identifying prognostic factors in pts with mBRAF mCRC in Russia. 

Materials and methods. A multicenter retrospective analysis of clinical data and treatment results of pts with mBRAF mCRC was 
performed. The main method for determining mutations was a PCR. The main efficacy endpoint was progression free survival (PFS) at the 1 st line. Multivariate analysis was performed using Cox regression model. 
Results and discussion. 437 out of 8648 pts (5.17%) with a known mutational status had mBRAF (V600). Clinical data were collected from 131/437 (30%): the right-sided primary tumor – in 58,6%, left-sided – in 19%, rectum – in 21,4%. ORR in pts with mBRAF was 31%, median PFS was 6 months. We didn’t revealed any differences between FOLFOXIRI and doublets (XELOX/
FOLFOX or XELIRI/FOLFIRI) in terms of PFS (HR 0.9, 95% CI 0.49–1.52, р = 0.6) and OS (HR 1.5, 95% CI 0.61–4.1, р = 0.35) in pts with mBRAF. 
Conclusions. The incidence of mBRAF gene in the population of pts with mCRC in the Russia is low and we found a high incidence of localization of the primary tumor in the rectum. We didn’t reveal any differences between the usual duplets and standard regimen for such mutation - FOLFOXIRI in term of 1 st line PFS. 

1. Nakhoda S., Deng M., Iyer P., Handorf E.A., Jain R., Meropol N.J., Dotan E. Assessing real-world biomarker testing rates in metastatic colon cancer. J Clin Oncol. 2020;38(4S):209. doi: 10.1200/JCO.2020.38.4_suppl.209.

2. Pietrantonio F., Petrelli F., Coinu A., Bartolomeo M.D., Borgonovo K., Maggi C. et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. Eur J Cancer. 2015;51(5):587–594. doi: 10.1016/j.ejca.2015.01.054.

3. Rowland A., Dias M.M., Wiese M.D., Kichenadasse G., McKinnon R.A., Karapetis C.S., Sorich M.J. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112(12):1888–1894. doi: 10.1038/bjc.2015.173.

4. Kopetz S., Grothey A., Yaeger R., Van Cutsem E., Desai J., Yoshino T. et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated colorectal cancer. N Engl J Med. 2019;381(17):1632–1643. doi: 10.1056/ NEJMoa1908075.

5. Yuan Z.-X., Wang X.-Y., Qin Q.-Y., Chen D.-F., Zhong Q.-H., Wang L., Wang J.-P. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One. 2013;8(6):e65995. doi: 10.1371/journal.pone.0065995.

6. Modest D.P., Ricard I., Heinemann V., Hegewisch-Becker S., Schmiegel W., Porschen R. et al. Outcome according to KRAS-, NRAS- and BRAFmutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol. 2016;27(9):1746–1753. doi: 10.1093/ annonc/mdw261.

7. Chu J.E., Johnson B., Morris V.K., Raghav K.P.S., Swanson L., Lim H.J. et al. Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis. J Clin Oncol. 2019;37(5S):3579. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_ suppl.3579.

8. Jones J.C., Renfro L.A., Al-Shamsi H.O., Schrock A.B., Rankin A., Zhang B.Y. et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J Clin Oncol. 2017;35(23):2624–2630. doi: 10.1200/JCO.2016.71.4394.

9. Yao Z., Yaeger R., Rodrik-Outmezguine V.S., Tao A., Torres N.M., Chang M.T. et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548(7666):234–238. doi: 10.1038/ nature23291.

10. Li H.T., Lu Y.Y., An Y.X., Wang X, Zhao Q.-C. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep. 2011;25(6):1691–1697. doi: 10.3892/or.2011.1217.

11. Nakanishi R., Harada J., Tuul M., Zhao Y., Ando K., Saeki H. et al. Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. Int J Clin Oncol. 2013;18:1042–1048. doi: 10.1007/s10147-0120501-x.

12. Bae J.M., Kim J.H., Cho N-Y., Kim T.Y., Kang G.H. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer. 2013;109:1004–1012. doi: 10.1038/ bjc.2013.430.

13. Richman S.D., Seymour M.T., Chambers P., Elliott F., Daly C.L., Meade A.M. et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27(35):5931–5937. doi: 10.1200/JCO.2009.22.4295.

14. Dahlin A.M., Palmqvist R., Henriksson M.L., Jacobsson M., Eklof V., Rutegard J. et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res. 2010;16(6):1845–1855. doi: 10.1158/1078-0432.CCR-09-2594.

15. Tie J., Gibbs P., Lipton L., Christie M., Jorissen R.N., Burgess A.W. et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation. Int J Cancer. 2011;128(9):2075–2084. doi: 10.1002/ijc.25555.

16. Tian S., Simon I., Moreno V., Roepman P., Tabernero J., Snel M. et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut. 2013;62(4):540–549. doi: 10.1136/gutjnl-2012-302423.

17. Lochhead P., Kuchiba A., Imamura Y., Liao X., Yamauchi M., Nishihara R. et al. Microsatellite instability and BRAF mutation testing in colorectal Cancer prognostication. J Natl Cancer Inst. 2013;105(15):1151–1156. doi: 10.1093/jnci/djt173.

18. Cheng H.H., Lin J.K., Chen W.S., Jiang J.K., Yang S.H., Chang S.C. Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer. Int J Colorectal Dis. 2018;33(9):1173–1181. doi: 10.1007/s00384-018-3095-6.

19. Loree J.M., Pereira A.A.L., Lam M., Willauer A.N., Raghav K., Dasari A. et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res. 2018;24(5):1062–1072. doi: 10.1158/1078-0432. CCR-17-2484.

20. Hernández-Sandoval J.A., Gutiérrez-Angulo M., Magaña-Torres M.T., AlvizoRodríguez C.R., Ramírez-Plascencia H.H.F., Flores-López B.A. et al. Prevalence of the BRAF p.v600e variant in patients with colorectal cancer from Mexico and its estimated frequency in Latin American and Caribbean populations. J Investig Med. 2020;68(5):985–991. doi: 10.1136/jim-2020-001301.

21. Kayhanian H., Goode E., Sclafani F., Ang J.E., Gerlinger M., de Castro D.G. et al. Treatment and survival outcome of BRAF-mutated metastatic colorectal cancer: a retrospective matched case-control study. Clin Colorectal Cancer. 2018;17(1):e69-e76. doi: 10.1016/j.clcc.2017.10.006.

22. Fedyanin M.Yu., Polyanskaya E.M., Elsnukaeva H.H., Tryakin A.A., Pokataev I.A., Bulanov A.A., Tjulandin S.A. FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis. Meditsinskiy sovet = Medical Council. 2020;(20):125–132. (In Russ.) doi: 10.21518/2079-701X-2020-20-125-132.

23. Cremolini C., Antoniotti C., Stein A., Bendell J., Gruenberger T., Rossini D. et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020;JCO2001225. doi: 10.1200/JCO.20.01225.

24. Roberto M., Marchetti P., Arrivi G., Di Pietro F.R., Cascinu S., Gelsomino F. et al. The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. Int J Colorectal Dis. 2020;35(8):1513–1527. doi: 10.1007/s00384-020-03589-9.

25. Tabernero J., Grothey A., Van Cutsem E., Yaeger R., Wasan H., Yoshino T. et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021;39(4):273–284. doi: 10.1200/JCO.20.02088.

26. Morris V.K., Kee B.K., Overman M.J., Fogelman D.R., Dasari A., Raghav K.P.S. et al. Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers. J Clin Oncol. 2020;38(15S):407. doi: 10.1200/JCO.2020.38.15_suppl.4047 .

27. Montañá J.R., Martini G., Baraibar I., Villacampa G., Comas R., Ciardiello D. et al. Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy. J Clin Oncol. 2020;38(15S):4112. doi: 10.1200/JCO.2020.38.15_suppl.4112.